Pediatric Chronic Pancreatitis

I. Overview

• Chronic pancreatitis (CP) is a progressive inflammatory disorder of the pancreas characterized by irreversible structural changes and fibrotic replacement of the pancreatic parenchyma, leading to permanent loss of exocrine and endocrine function and significant disease burden.
• CP may be preceded by episodes of acute recurrent pancreatitis (ARP), particularly in children with genetic susceptibility.
• Risk factors for CP include:
  • Genetic
  • Obstructive
  • Toxic/metabolic
  • Autoimmune
  • Idiopathic

II. Genetic Disorders (Most Common in Pediatric Age Group)

A. Cationic Trypsinogen (PRSS1)

• Proteolytic enzyme produced by acinar cells.
• First hereditary pancreatitis gene identified in 1996.
• Autosomal dominant inheritance with ~80% penetrance and strong family history.
• Common mutations:
  • R122H: histidine replaces arginine at position 122
  • N29I: isoleucine replaces asparagine at position 29
• Mutations lead to gain of function by increasing activation or preventing inactivation of trypsin → pancreatic autodigestion.
• Clinical features:
  • Recurrent pancreatitis starting at ages 10–14
  • 50% develop CP within 10 years
  • Increased risk for type IIIc diabetes and pancreatic adenocarcinoma

B. Chymotrypsin C (CTRC)

• Proteolytic enzyme that degrades trypsin.
• Mutations R254W and K247_R254del are overrepresented in idiopathic/hereditary CP.
• Loss-of-function mutations reduce protective trypsin-degrading activity → predisposition to CP.

C. Serine Protease Inhibitor, Kazal Type 1 (SPINK1)

• Pancreatic secretory trypsin inhibitor secreted by acinar cells.
• 1–4% of general population are carriers without disease.
• Most common mutation: N34S (asparagine to serine at codon 34).
• Mechanism:
  • Uninhibited trypsin activation in ducts
  • Acts as a genetic cofactor, not a sole cause
• 90% of affected patients present with acute pancreatitis by age 20.

D. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

• Pancreatitis results from thickened secretions causing ductal obstruction and autodigestion.
• 10–20% of pancreatic-sufficient CF patients present with ARP or CP.
• 17–43% of idiopathic pancreatitis patients have CFTR mutations.
• Risk increases with coexisting SPINK1 mutations.

E. Carboxypeptidase A1 (CPA1)

• Second largest protein component in pancreatic fluid after trypsinogens.
• Mutations may cause ER stress rather than increased trypsin activity.
• Overrepresented in nonalcoholic CP, especially in children under 10.

F. Carboxyl Ester Lipase (CEL) and CEL-Hybrid Allele (CEL-HYB)

• CEL is expressed in acinar cells.
• Single-base deletions in CEL VNTR region cause MODY type 8 (diabetes + exocrine insufficiency).
• CEL-HYB is a crossover between CEL and pseudogene CELP.
• Mechanism may involve reduced secretion, cellular accumulation, and autophagy.
• CEL-HYB is overrepresented in familial pancreatitis compared to controls.

III. Obstructive Causes

• Identified in up to one-third of pediatric patients with chronic pancreatitis (CP).
• Congenital structural abnormalities:
  • Pancreas divisum:
    • Most common structural abnormality in pediatric CP.
    • Occurs in ~20% of pediatric CP patients vs ~7% of general population.
    • Often considered a cofactor, especially when genetic mutations (e.g., PRSS1, SPINK1) are present (~50%).
  • Choledochal cysts and anomalous pancreaticobiliary ductal union:
    • Frequently co-occur.
    • Bile reflux into pancreatic duct may trigger ARP and CP.
  • Annular pancreas and duodenal webs: Rare but may cause ductal obstruction.
• Idiopathic fibrosing pancreatitis:
  • Very rare; presents with obstructive jaundice, abdominal pain, and pancreatitis.
  • Characterized by pancreatic fibrosis ± inflammation.
  • Associated with PRSS1, SPINK1, and CFTR 5T mutations.
• Sphincter of Oddi dysfunction: Poorly studied in children; may contribute to ARP episodes.
• Abdominal trauma: Can lead to ductal injury and pancreatitis.
• Gallstones and microlithiasis: More common in adolescents; may be underdiagnosed in younger children.
• Acquired strictures and intraductal calculi:
  • May result from prior pancreatitis, trauma, or surgical anastomosis.

IV. Other Causes

• Etiologies of ARP and CP often overlap; any ARP risk factor should be considered in CP evaluation.
• Toxic/Metabolic:
  • Alcohol: Common in adult CP; rarely implicated in pediatric cases.
  • Smoking: Associated with advanced CP in adults; pediatric effects (active, passive, fetal exposure) remain poorly studied.
  • Hypertriglyceridemia: Risk increases when triglycerides > 1,000 mg/dL.
  • Other metabolic triggers: Hypercalcemia, organic acidemias, medications, diabetic ketoacidosis.
• Autoimmune Pancreatitis:
  • Rare and poorly defined in children.
  • IgG4 may be elevated, but pediatric cases may present with normal IgG4 levels.
  • Histology: ductal/periductal lymphoplasmacytic infiltration, irregular duct narrowing, pancreatic enlargement.
  • Responsive to corticosteroids.
• Tropical CP:
  • Endemic in regions like India and Africa.
  • May involve environmental and nutritional factors (e.g., cassava, micronutrient deficiency).
• Idiopathic: Diagnosis made after exclusion of known causes.

V. Clinical Presentation

• Repeated attacks of acute pancreatitis (AP) or acute episodes superimposed on chronic pancreatitis (CP).
• Abdominal pain:
  • Usually in the upper abdomen
  • Episodic or persistent
  • Mild to moderate or severe intensity
• Nausea and/or vomiting; anorexia may be present.
• Symptoms and signs of exocrine pancreatic insufficiency (EPI):
  • Steatorrhea
  • Weight loss
  • Fat-soluble vitamin deficiencies
• Type IIIc (pancreatogenic) diabetes mellitus:
  • Occurs in 40–70% of adults with CP after ~12–25 years
• Pancreatic adenocarcinoma risk:
  • 4% lifetime risk in CP patients
  • Up to ~40% risk in patients with PRSS1 mutations

VI. Diagnostic Testing

• CP is typically defined by characteristic imaging findings plus ≥1 of the following:
  • Abdominal pain of pancreatic origin
  • Exocrine pancreatic insufficiency (EPI)
    • Indirect tests preferred: fecal elastase, 72-hour fecal fat
    • Direct tests (e.g., Dreiling tube, endoscopic pancreatic function test) are less commonly used
  • Endocrine pancreatic insufficiency
    • Most commonly diagnosed via oral glucose tolerance test
• Characteristic imaging findings may be seen on:
  • Ultrasound (US)
  • Magnetic resonance cholangiopancreatography (MRCP)
  • Endoscopic retrograde cholangiopancreatography (ERCP)
  • Endoscopic ultrasound (EUS)
  • Computed tomography (CT)
• Imaging features:
  • Ductal changes: irregular contour (beading), intraductal filling defects, calculi, stricture, dilation
  • Parenchymal changes: enlargement, irregular contour, cavities, calcifications, heterogeneous echotexture
• Recommended initial evaluation for children with ARP or CP:
  • Genetic testing: PRSS1, SPINK1, CFTR, CTRC
  • Secretin-enhanced MRCP: preferred first-line imaging
  • Alternatives: CT, EUS, ERCP
  • RUQ ultrasound and liver function tests for gallstones
  • Fasting lipids and total serum calcium
  • Sweat chloride test
• Controversial or second-line tests (only if clinically indicated):
  • Serum ammonia (NH₃)
  • Urine organic acids
  • Serum IgG4 levels
  • Pancreatic biopsy ± IgG4 staining
  • Sphincter of Oddi manometry
  • Celiac testing
  • Endoscopic inspection of duodenum and major papilla
• Patients with ARP/CP and increasing AP episodes may benefit from repeat imaging to assess for treatable sequelae (e.g., ductal strictures or stones).

VII. Management

A. Medical

• Treatment of acute episodes:
  • Conservative management
  • Pain control
  • Hydration
• Management of exocrine pancreatic insufficiency (EPI):
  • Pancreatic enzyme replacement therapy (PERT)
  • Balanced nutrition
  • Fat-soluble vitamin supplementation if needed
• Pain control:
  • First-line: acetaminophen and NSAIDs
  • Stepwise use of short- and long-acting narcotics
  • Consider addictive potential and GI side effects
  • Tramadol and gabapentin have shown efficacy in adults
• Supplemental pancreatic enzymes and antioxidant therapy:
  • Role remains unestablished

B. Endoscopic

• May be helpful for ductal strictures with obstruction.
• Stent placement and/or sphincterotomy for pancreas divisum is controversial, especially in pediatric patients.

C. Surgical

• Considered for chronic, debilitating pain.
• Decompressive procedures are generally favored over resections in children.
• Puestow procedure (longitudinal pancreatojejunostomy):
  • Opens the pancreatic duct along the body and tail to the oversewn jejunum.
  • Effectiveness in resolving pain and preventing attacks is variable.
• Total pancreatectomy with islet cell autotransplantation (TP-IAT):
  • Removes fibrotic pancreas and infuses isolated islets into the portal vein.
  • Goal: pain relief and preservation of endocrine function.
  • Risks:
    • Predisposes to brittle diabetes
  • Outcomes:
    • ~60% of children are narcotic-free and insulin-independent at 2.5 years
    • Quality of life improves within 1 year
      

References:

1. Abu-El-Haija, M., Kumar, S., Szabo, F., Werlin, S., Conwell, D., & Morinville, V. D. (2017). Classification of acute pancreatitis in the pediatric population: Clinical report from the NASPGHAN Pancreas Committee. Journal of Pediatric Gastroenterology and Nutrition, 64(6), 984–990. https://doi.org/10.1097/MPG.0000000000001522
2. Schwarzenberg, S. J., Bellin, M., Husain, S. Z., Lin, T. K., Alhosh, M., Lowe, M. E., & Barth, B. (2015). Pediatric chronic pancreatitis is associated with genetic risk factors and substantial disease burden. Journal of Pediatric Gastroenterology and Nutrition, 61(2), 204–210. https://doi.org/10.1097/MPG.0000000000000780
3. Morinville, V. D., Husain, S. Z., Bai, H., Barth, B., Alhosh, M., Durie, P. R., & Lowe, M. E. (2012). Definitions of pediatric pancreatitis and survey of current clinical practices: Report from INSPPIRE. Journal of Pediatric Gastroenterology and Nutrition, 55(3), 261–265. https://doi.org/10.1097/MPG.0b013e31824b97f1
4. Lin, T. K., Abu-El-Haija, M., & Nathan, J. D. (2020). Pediatric pancreatitis: Update on pathophysiology, diagnosis, and management. Current Opinion in Pediatrics, 32(3), 356–363. https://doi.org/10.1097/MOP.0000000000000899
5. Bellin, M. D., & Lowe, M. E. (2020). Pediatric pancreatitis: Insights from the INSPPIRE consortium. Pancreatology, 20(3), 427–431. https://doi.org/10.1016/j.pan.2020.01.003
6. Giefer, M. J., & Lowe, M. E. (2014). Chronic pancreatitis in children. Journal of Pediatric Gastroenterology and Nutrition, 58(1), 91–96. https://doi.org/10.1097/MPG.0000000000000142
7. Werlin, S. L., & Conwell, D. L. (2018). Pancreatitis in children and adolescents. In R. Wyllie, J. S. Hyams, & M. Kay (Eds.), Pediatric Gastrointestinal and Liver Disease (5th ed., pp. 663–674). Elsevier.
8. Tang, G., & Bellin, M. D. (2021). Total pancreatectomy with islet autotransplantation in children: Indications, outcomes, and future directions. Current Opinion in Endocrinology, Diabetes and Obesity, 28(1), 45–51. https://doi.org/10.1097/MED.0000000000000590
9. Hart, P. A., Zen, Y., & Chari, S. T. (2015). Recent advances in autoimmune pancreatitis. Gastroenterology, 149(1), 39–51. https://doi.org/10.1053/j.gastro.2015.04.010
10. Lucidi, V., Alghisi, F., Dall'Oglio, L., D'Apice, M. R., Monti, L., De Angelis, P., & Cucchiara, S. (2009). The etiology of acute recurrent pancreatitis in children: A challenge for pediatricians